Benitec Biopharma Inc. Common Stock (BNTC) Stock Price

BNTCStock

$12.47−4.30%52W

Market Cap$428.40M

P/E—

PEG Ratio—

Div yield—

Beta0.25

BNTC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)0.21%

Price vs S&P 500 (4W)1.09%

VGM Score34.51

Book Value / Share (Quarterly)$3.57

P/TBV (Annual)40.75x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)-20.25%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-20671.43%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.17M

EPS Excl Extra (TTM)$-1.11

EPS (Annual)$-1.05

ROI (Annual)-46.28%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-16368.59%

Cash / Share (Quarterly)$3.60

ROA (Last FY)-41.83%

EBITD / Share (TTM)$-1.21

ROE (5Y Avg)-2121.74%

Operating Margin (TTM)-20714.29%

Cash Flow / Share (Annual)$-1.96

P/B Ratio4.61x

P/B Ratio (Quarterly)3.93x

Net Income / Employee (Annual)$-1,995,600

EV / Revenue (TTM)4814.45x

Net Interest Coverage (TTM)-42.47x

ROA (TTM)-44.04%

EPS Incl Extra (Annual)$-1.05

Current Ratio (Annual)10.57x

Quick Ratio (Quarterly)46.72x

3-Month Avg Trading Volume0.13M

52-Week Price Return-4.30%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)5393.63x

Asset Turnover (Annual)0.02x

52-Week High$16.76

Operating Margin (5Y Avg)-16055.53%

EPS Excl Extra (Annual)$-1.05

CapEx CAGR (5Y)-29.03%

Tangible BV CAGR (5Y)-57.08%

26-Week Price Return12.14%

Quick Ratio (Annual)10.46x

13-Week Price Return7.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)46.95x

Enterprise Value$337.01M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-33.13%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-24450.00%

Cash / Share (Annual)$5.10

3-Month Return Std Dev53.70%

Gross Margin (5Y Avg)94.40%

Net Income / Employee (TTM)$-2,572,800

ROE (Last FY)-46.28%

Net Interest Coverage (Annual)-68.59x

EPS Basic Excl Extra (Annual)$-1.05

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)2.67x

ROI (TTM)-45.91%

P/S Ratio (TTM)6164.15x

Pretax Margin (5Y Avg)-16368.59%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.12

Price vs S&P 500 (52W)-22.86%

Year-to-Date Return-7.42%

5-Day Price Return-1.89%

EPS Normalized (Annual)$-1.05

ROA (5Y Avg)-184.34%

Net Profit Margin (Annual)-24450.00%

Month-to-Date Return6.49%

Cash Flow / Share (TTM)$-14.00

EBITD / Share (Annual)$-1.13

Operating Margin (Annual)-23850.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-2121.74%

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)40.75x

P/B Ratio (Annual)1.45x

Pretax Margin (TTM)-20671.43%

Book Value / Share (Annual)$4.70

Price vs S&P 500 (13W)5.92%

Beta0.25x

P/FCF (Annual)114.15x

Revenue / Share (TTM)$0.00

ROE (TTM)-45.91%

52-Week Low$9.85

vGradeF

mGradeC

vgmGradeD

BNTC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 14, 2026	-$0.28	-$0.24	+12.73%(+$0.04)
Q4 2025	Feb 12, 2026	-$0.23	-$0.26	-15.04%(-$0.03)
Q3 2025	Nov 14, 2025	-$0.36	-$0.22	+38.20%(+$0.14)
Q2 2025	Sep 22, 2025	-$0.31	-$0.42	-34.25%(-$0.11)

BNTC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.38

4.31

4.25

4.31

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
BNTCBenitec Biopharma Inc. Common Stock	F	—	C	$12.47
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Benitec Biopharma Inc. Common Stock

Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines designed to provide one-time curative treatments. The company's lead program, BB-301, is a silence-and-replace therapeutic targeting Oculopharyngeal Muscular Dystrophy (OPMD), a rare, chronic genetic disorder with no currently effective treatments.